Shukra Pharmaceuticals Limited has announced a strategic move into advanced medical technology after entering into a Memorandum of Understanding (MoU) with US-based Borns Medical Robotics Inc., a globally recognised name in robotic surgical technologies. The MoU was received on January 05, 2026, marking a significant step in the company’s long-term growth and diversification strategy.
Under the proposed collaboration, the two companies plan to introduce, promote and commercialise next-generation AI-enabled soft-tissue surgical robotic systems across India and select South Asian markets. These include Nepal, Bangladesh, Sri Lanka, Maldives and Bhutan, subject to regulatory approvals in the respective regions. The execution of the entire project will be undertaken through Shukra Robotics Pvt. Ltd., a subsidiary of Shukra Pharmaceuticals Limited.
The association is aimed at expanding access to advanced robot-assisted minimally invasive surgeries by leveraging high-precision, stability-driven robotic platforms. A key focus area of the collaboration is the integration of artificial intelligence with digital surgery workflows, which is expected to enable more standardised surgical procedures while improving overall clinical efficiency. The initiative also seeks to strengthen regional healthcare infrastructure through technology transfer, structured clinician training programmes and scalable deployment models.
Borns Medical Robotics Inc. will contribute its expertise in surgical robotics platforms and AI-enabled technologies, while Shukra Pharmaceuticals Limited will utilise its established regulatory execution capabilities, strong healthcare market presence and distribution reach across India and South Asia. This combination is expected to accelerate the adoption of cutting-edge surgical robotics in emerging healthcare markets.
According to the company, the proposed collaboration aligns closely with its vision of diversifying into high-value, technology-driven healthcare segments. By entering the surgical robotics space, Shukra Pharmaceuticals aims to enhance its consolidated business portfolio and strengthen its market positioning in advanced medical technologies. The company also expects to unlock new revenue opportunities through commercialisation, hospital partnerships and the development of a broader healthcare ecosystem around robotic-assisted surgeries.
